腎臓がん薬市場：治療別、薬理学的クラス別：薬理学的クラス別、流通チャネル別、地域別

世界の腎臓がん薬市場は、2025年には73億1,000万米ドルと推定され、2032年には110億7,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR6.1％で成長すると予測されます。

図.腎臓がん薬市場シェア（%）、2025年地域別

医薬品分析試験とは、腎臓がん（腎細胞がんとしても知られる）を確定するための科学的技術や手法の使用を指します。腎臓がんは、世界的に最も一般的ながんのひとつになりつつあります。推定によると、世界中で毎年40万人以上が新たに診断されています。腎臓がんに関連する危険因子としては、タバコの使用、肥満、遺伝性因子、特定の毒素への暴露などが挙げられます。早期の腎臓がんでは自覚症状がない場合もあるが、尿に血が混じったり、脇腹が痛んだり、腹部の腫瘤を認める患者もいます。治療の選択肢は、限局した病変に対する腎部分切除術や根治的腎摘除術から、進行例に対する標的療法や免疫療法まで多岐にわたる。全体として、世界の腎臓がん薬市場は、罹患率の上昇、先進治療への患者アクセスの改善、新薬の強力なパイプラインなどの要因が引き続き市場の成長を支えていることから、今後数年間で大きく成長すると予想されます。

市場力学：

世界の腎臓がん薬市場は、世界の腎細胞がんの有病率の上昇によって牽引されています。高齢者人口の増加、肥満率の上昇、職場における毒素への曝露の増加といったリスク因子の増加が、疾患罹患率の上昇に寄与しています。さらに、先進国におけるプレミアム標的療法や免疫療法への患者アクセスの改善が、市場の成長を支えています。同時に、手術、放射線治療、薬物療法を組み合わせた治療期間が長期化することで、患者は維持療法に依存する期間が長くなっています。市場開拓には有利な成長機会がある一方で、主要医薬品の特許切れやジェネリック医薬品の市場参入といった要因が、大手開発企業の収益源を阻害する可能性があります。さらに、新興国市場における高い価格設定と購入しやすい価格の問題は、より広範な市場へのアクセスを制限しています。とはいえ、さまざまな疾患経路をターゲットとする臨床試験中の分子パイプラインは充実しており、将来的な市場拡大の可能性を秘めています。

本調査の主な特徴

• 本レポートでは、世界の腎臓がん薬市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の腎臓がん薬市場における主要企業プロファイルを掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の腎臓がん薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の腎臓がん薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 主な発展
• 規制シナリオ
• 買収と提携のシナリオ
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の腎臓がん薬市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 世界の腎臓がん薬市場、治療別、2020年-2032年（10億米ドル）

• 標的療法
• 免疫療法
• 化学療法

第6章 世界の腎臓がん薬市場、薬理学的クラス別、2020年-2032年、（10億米ドル）

• 血管新生阻害剤
• mTOR阻害剤
• サイトカイン
• その他（免疫チェックポイント阻害剤、CTLA-4阻害剤、代謝拮抗剤など）

第7章 世界の腎臓がん薬市場、流通チャネル別、2020年-2032年、（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界の腎臓がん薬市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • Pfizer Inc.
  • 3D Systems
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG（Genentech, Inc.）
  • Bayer AG
  • Exelixis, Inc.
  • Merck &Co., Inc.
  • Eisai Co., Ltd.
  • Aveo Pharmaceuticals
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

第10章 アナリストの推奨事項

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Kidney Cancer Drugs Market is estimated to be valued at USD 7.31 Bn in 2025 and is expected to reach USD 11.07 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.

Figure. Kidney Cancer Drugs Market Share (%), By Region 2025

Pharmaceutical analytical testing refers to the use of scientific techniques and methods to establish kidney cancer, also known as renal cell carcinoma. It is becoming one of the most common cancers globally. According to estimates, over 400,000 new cases are diagnosed worldwide each year. Risk factors associated with kidney cancer include tobacco use, obesity, hereditary factors, and exposure to certain toxins. While early-stage disease may present no symptoms, some patients may see blood in urine, flank pain, or an abdominal mass. Treatment options range from partial or radical nephrectomy for localized disease to targeted therapies or immunotherapy for advanced cases. Overall, the global kidney cancer drugs market is expected to grow significantly in the coming years as factors such as rising incidence of disease, improving patient access to advanced treatments, and robust pipeline of novel drugs continue to support the market growth.

Market Dynamics:

The global kidney cancer drugs market is driven by the rising prevalence of renal cell carcinoma worldwide. Growing risk factors, such as increasing geriatric population, rising obesity rates, and greater exposure to toxins at the workplace, are contributing to the rising disease incidence. Additionally, improving patient access to premium targeted therapies and immunotherapies in developed nations are supporting the market growth. At the same time, lengthy duration of treatment involving combinations of surgery, radiotherapy, and drug regimens is keeping patients dependent on maintenance therapies for longer duration. While the market sees lucrative growth opportunities, factors such as patent expiration of major drugs and market entry of generics could hamper the revenue stream of leading developers. Moreover, high pricing and affordability issues in developing nations restrict broader market access. Nevertheless, robust pipeline of molecules under clinical trials targeting different disease pathways offers potential for market expansion in future.

Key Features of the Study:

• This report provides in-depth analysis of the global kidney cancer drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global kidney cancer drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Pfizer Inc., Novartis AG, Bayer AG, Amgen, F. Hoffmann-La Roche Ltd, and Eisai Co. Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation-

• By Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
• By Pharmacological Class
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Cytokines
  • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Pfizer Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Roche Holding AG (Genentech, Inc.)
  • Bayer AG
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Eisai Co., Ltd.
  • Aveo Pharmaceuticals
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy
  • Market Snapshot, By Pharmacological Class
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Kidney Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Kidney Cancer Drugs Market, By Therapy, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Kidney Cancer Drugs Market, By Pharmacological Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Angiogenesis Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• mTOR Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cytokines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Kidney Cancer Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Kidney Cancer Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Pharmacological Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • 3D Systems
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Roche Holding AG (Genentech, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Exelixis, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eisai Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aveo Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca PLC
  • Ipsen Biopharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Abbott Laboratories Source
  • Amgen Inc.
  • Calithera Biosciences, Inc.
  • Active Biotech
  • Immatics Biotechnologies GmbH
  • Karyopharm Therapeutics

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact